BCMA-directed CAR T-cell therapy is drastically changing the multiple myeloma treatment landscape.
UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners
Latest from UCSF Helen Diller Family Comprehensive Cancer Center
The addition of immunotherapy to the triple-negative breast cancer (TNBC) armamentarium has led to a paradigm shift and sparked an abundance of research with immuno-oncology (IO) drugs in new combinations and settings, explained Hope S. Rugo, MD.
CAR T-cell therapy is poised to have a significant impact on the treatment of patients with relapsed/refractory multiple myeloma, says Nina Shah, MD.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Progression Occurs Early in R/R LBCL Treated With Epcoritamab, Glofitamab
2
Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML
3
Sacituzumab Govitecan Fails to Reach Significant PFS in HR+/HER2– mBC
4
Frontline Axi-Cel CR Linked With Improved Survival in High-Risk LBCL
5
